NASDAQ:ALGS Aligos Therapeutics (ALGS) Stock Price, News & Analysis $7.69 -0.44 (-5.41%) Closing price 04:00 PM EasternExtended Trading$7.60 -0.09 (-1.17%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Aligos Therapeutics Stock (NASDAQ:ALGS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aligos Therapeutics alerts:Sign Up Key Stats Today's Range$7.54▼$8.4950-Day Range$5.25▼$9.2852-Week Range$3.76▼$46.80Volume84,987 shsAverage Volume67,113 shsMarket Capitalization$46.99 millionP/E RatioN/ADividend YieldN/APrice Target$70.00Consensus RatingBuy Company Overview Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Read More Aligos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks88th Percentile Overall ScoreALGS MarketRank™: Aligos Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 139th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAligos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAligos Therapeutics has received no research coverage in the past 90 days.Read more about Aligos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aligos Therapeutics are expected to decrease in the coming year, from ($10.36) to ($11.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aligos Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aligos Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAligos Therapeutics has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.29% of the float of Aligos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aligos Therapeutics has recently decreased by 26.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAligos Therapeutics does not currently pay a dividend.Dividend GrowthAligos Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.80 Percentage of Shares Shorted9.29% of the float of Aligos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aligos Therapeutics has recently decreased by 26.47%, indicating that investor sentiment is improving significantly. News and Social Media3.0 / 5News Sentiment0.40 News SentimentAligos Therapeutics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aligos Therapeutics this week, compared to 1 article on an average week.Search Interest7 people have searched for ALGS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Aligos Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Aligos Therapeutics is held by insiders.Percentage Held by Institutions60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aligos Therapeutics' insider trading history. Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALGS Stock News HeadlinesAligos Therapeutics reports Q2 EPS ($1.53), consensus ($2.54)August 7 at 5:24 AM | msn.comAligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial ResultsAugust 6 at 4:05 PM | globenewswire.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.August 8 at 2:00 AM | Brownstone Research (Ad)Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on WednesdayAugust 4, 2025 | americanbankingnews.comAligos Therapeutics (NASDAQ:ALGS) Will Have To Spend Its Cash WiselyJuly 31, 2025 | finance.yahoo.comAligos Therapeutics, Inc. to Announce Second Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | quiverquant.comQAligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025July 30, 2025 | globenewswire.comAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 | globenewswire.comSee More Headlines ALGS Stock Analysis - Frequently Asked Questions How have ALGS shares performed this year? Aligos Therapeutics' stock was trading at $39.84 on January 1st, 2025. Since then, ALGS stock has decreased by 80.7% and is now trading at $7.69. How were Aligos Therapeutics' earnings last quarter? Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced its quarterly earnings data on Wednesday, August, 6th. The company reported ($1.53) earnings per share for the quarter, topping the consensus estimate of ($2.35) by $0.82. The firm had revenue of $0.97 million for the quarter, compared to analysts' expectations of $0.43 million. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative trailing twelve-month return on equity of 22.41%. When did Aligos Therapeutics' stock split? Aligos Therapeutics's stock reverse split on Monday, August 19th 2024.The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Aligos Therapeutics IPO? Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager. Who are Aligos Therapeutics' major shareholders? Top institutional investors of Aligos Therapeutics include Geode Capital Management LLC (0.56%), AlphaQuest LLC (0.10%) and Quaker Wealth Management LLC. View institutional ownership trends. How do I buy shares of Aligos Therapeutics? Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aligos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aligos Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Athenex (ATNX), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Adverum Biotechnologies (ADVM). Company Calendar Last Earnings8/06/2025Today8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALGS CIK1799448 Webwww.aligos.com Phone800-466-6059FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Aligos Therapeutics$70.00 High Price Target$70.00 Low Price Target$70.00 Potential Upside/Downside+806.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($19.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$131.21 million Net Margins-2,337.24% Pretax Margin-1,618.04% Return on Equity-29.25% Return on Assets-13.01% Debt Debt-to-Equity RatioN/A Current Ratio7.56 Quick Ratio7.56 Sales & Book Value Annual Sales$3.94 million Price / Sales11.97 Cash FlowN/A Price / Cash FlowN/A Book Value($7.50) per share Price / Book-1.03Miscellaneous Outstanding Shares6,110,000Free Float5,821,000Market Cap$47.17 million OptionableNo Data Beta2.77 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:ALGS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.